FSE$QGEN

QIAGEN · Q1 2026 earnings

Q1 2026 earnings · · After market close · Investor relations

Briefing

QIAGEN Q1 2026: $492M net sales up 2% as margins compress on tariffs and Parse costs

QIAGEN reported first-quarter 2026 U.S. GAAP results on May 7, 2026, with net sales of $492.3 million, up 2% year over year, driven by 2% growth in consumables while instruments declined 2%. Net income fell to $68.0 million from $90.8 million a year earlier as operating income margin compressed to 17.1% from 23.9%, reflecting tariff and currency headwinds plus Parse Biosciences integration costs, partially offset by restructuring savings. The company returned $496.7 million to shareholders through a synthetic capital repayment that reduced shares outstanding by 5.0%. Operating cash flow declined to $100.6 million from $139.7 million in the prior-year quarter.

  • Net sales rose 2% to $492.3M with consumables up 2% and instruments down 2%.
  • Net income fell to $68.0M and diluted EPS was $0.33 versus $0.41 a year ago.
  • Operating income margin compressed to 17.1% on tariffs, currency moves, and Parse integration costs.
  • Sample technologies revenue grew strongly while diagnostic solutions was slightly lower.
  • A $496.7M synthetic capital repayment reduced outstanding shares by 5.0% in the quarter.

Headline financials

Total Revenue

$492M

Previous: $483M+1.9%
EPS (adj)

$0.33

Previous: $0.55-40.0%
Operating income margin

17.1%

No prior period
Operating cash flow

$101M

Previous: $140M-28.1%
Net Income

$68M

No prior period
Operating Income

$84.4M

No prior period
Gross Profit

$310M

No prior period
Cash & Equivalents

$646M

No prior period

Revenue & EPS history

QIAGEN · Revenue · Quarterly

$492M

Q1 2026+1.9%vs Q1 2025
Beat estimate in 8 of 13 quarters(62%)
ActualEstimate

Revenue by segment

QIAGEN · $847M total across 4 segments · Q1 2026

  • Consumables and related revenues
    $445M
  • Diagnostic solutions
    $185M
  • Sample technologies
    $170M
  • Instruments
    $47.5M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+0.5%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+3.0%

Avg return

30 days after

50%

32 / 64 earnings

Positive

+16.1%

Q2 2016

Best reaction

-6.2%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.3%-13.5%-3.8%
Q4 2025-0.9%-1.2%-13.8%
Q3 2025-3.6%-2.2%+6.5%
Q2 2025-3.1%+3.1%+0.1%
Q1 2025+1.7%-0.7%+10.3%
Q4 2024-2.1%-7.6%-8.3%
Q3 2024+0.4%+0.2%-1.2%
Q2 2024+2.4%+0.4%+2.2%
Q1 2024+1.6%+3.2%+2.2%
Q4 2023+3.1%+5.5%+5.5%
Q3 2023+3.7%+8.6%+14.2%
Q2 2023-1.1%-3.3%-6.9%
Q1 2023+3.8%+3.9%+4.8%
Q4 2022+0.1%-0.2%-7.1%
Q3 2022+3.8%+12.9%+14.6%
Q2 2022+1.9%+4.7%+1.0%
Q1 2022+0.3%+0.4%+1.0%
Q4 2021+0.8%-3.1%-11.3%
Q3 2021+0.9%-1.5%-1.7%
Q2 2021+2.3%+1.7%+7.5%
Q1 2021-0.4%-1.0%-2.2%
Q4 2020-1.4%+0.4%-12.9%
Q3 2020-1.1%-3.7%-4.1%
Q2 2020-3.8%-3.3%-4.0%
Q1 2020+1.8%+2.7%+4.9%
Q4 2019+3.8%+5.7%+23.7%
Q3 2019+2.9%+6.1%+47.7%
Q2 2019-1.6%-3.0%-9.8%
Q1 2019-5.5%-5.7%-0.5%
Q4 2018-0.9%-0.3%+6.7%
Q3 2018+4.7%+8.4%+3.0%
Q2 2018+4.1%+5.4%+8.1%
Q1 2018+4.0%+5.0%+11.2%
Q4 2017+0.6%-4.9%-3.2%
Q2 2017-3.4%-4.0%-8.1%
Q1 2017+2.1%+5.6%+11.6%
Q4 2016+1.1%+0.4%+0.9%
Q3 2016+7.6%+12.6%+11.8%
Q2 2016+16.1%+15.8%+15.5%
Q1 2016-4.0%
Q4 2015-2.0%
Q3 2015-6.2%
Q2 2015+2.2%
Q1 2015-0.2%
Q4 2014-1.2%
Q3 2014+1.0%
Q2 2014-0.5%
Q4 2013-3.7%
Q2 2013+1.1%
Q1 2013-3.7%
Q4 2012+6.6%
Q3 2012+3.8%
Q2 2012-0.2%
Q1 2012-0.2%
Q4 2011-1.0%
Q3 2011-1.8%
Q2 2011+1.4%
Q1 2011+1.4%
Q4 2008-0.1%
Q4 2010-0.1%
Q4 2009-0.1%
Q3 2010-1.7%
Q1 2010-1.2%
Q2 2010-1.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro